Antoine Boulanger - Profile and Investment Details

Investor Profile

Antoine Boulanger is a Venture Capital, Private Equity Firm, Investment Partner, Investor based in France with a diverse investment portfolio that includes companies such as Santaris Pharma, AM Pharma, Pathway Medical Technologies, Impella Cardiosystems, Borean Pharma, Roche Glycart, NovoGIOxyrane UK, OMEICOS Therapeutics, Inflazome, Amakem, Pulmologix, Ardana Bioscience, CoviCept Therapeutics, Rigontec, FlowMedica, Oxular, NeRRe Therapeutics, Hookipa Pharma, NorthSea Therapeutics, SANIFIT, PneumRx, Gotham Therapeutics, Catalym, Insmed, Mitralign, Prilenia, KaNDy Therapeutics, Ario Pharma, Cardoz, CircuLite, BioVex, Cytheris, Bluebird Bio, Pieris AG, UniQure, CellNovo, Akarna Therapeutics, Escalier Biosciences, Azafaros, Enterprise Therapeutics, Bioceros, Replimune Group, Exosome Diagnostics, Acorda Therapeutics, Dyne Therapeutics, gIcare Pharma, Amphista Therapeutics, Milestone Pharmaceuticals, Dezima Pharma, Fovea Pharmaceuticals, Inversago Pharma, Gyroscope Therapeutics, New Amsterdam Pharma, Autonomic Technologies, Xention, Achilles Therapeutics, arGEN-X, Curetis, ACADIA Pharmaceuticals, Allecra Therapeutics, PanGenetics, Promedior, Transave, Argos Therapeutics, enGene, Prexton Therapeutics, . Over time, Antoine Boulanger has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Antoine Boulanger is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Creative Venture, Health Care, Talent Management, Regenerative Medicine, Genetics, Disruptive Innovation, Wellness, Enterprise Software, Healthcare Innovation, Life Science, Portfolio Management, Finance, Biotechnology, Drug Development, Cofounder, Electronic Health Records (EHR), Genomics, Health and Hospital Services, Clinical Trials, Consumer Software, Personalized Medicine, Health Diagnostics, Digital Health, Medical, Big Data, Information Technology, B2B, Real Estate, Therapeutics, Health Tech, Cellular Therapy, Healthcare Payments, Media and Entertainment, Pharmaceuticals, Risk Management may find it worthwhile to explore potential connections with Antoine Boulanger, as their portfolio suggests a familiarity and interest in this area.

Understanding Antoine Boulanger’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.